Clinical observation of venetoclax-based treatment regimens for acute myeloid leukemia
10.3760/cma.j.cn115356-20220607-00166
- VernacularTitle:以维奈克拉为基础方案治疗急性髓系白血病的临床观察
- Author:
Jiayu HUANG
1
;
Zeying YAN
;
Haimin SUN
;
Ying WANG
;
Zhiyin LIU
;
Ran AN
;
Yubao CHEN
;
Yu CHEN
;
Sujiang ZHANG
Author Information
1. 上海交通大学医学院附属瑞金医院血液科 上海血液学研究所 国家转化医学中心，上海 200025
- Keywords:
Leukemia, myeloid, acute;
Venetoclax;
Drug therapy, combination;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2023;32(6):343-347
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate clinical efficacy and safety of venetoclax (VEN)-based regimens in the treatment of acute myeloid leukemia (AML).Methods:The clinical data of 41 AML patients treated with venetoclax-based regimens from January 2021 to December 2021 in Ruijin Hospital North of Shanghai Jiao Tong University School of Medicine were retrospectively analyzed. The treatment regimens included VEN+demethylating drugs ± gene mutation inhibitors or VEN+chemotherapy with a median number of 2 courses (1- 5 courses).Results:The median age of all patients was 60 years (18-73 years), and there were 24 males and 17 females. After 1 course of VEN-based therapy, 22 (53.7%) patients achieved complete remission (CR) or morphological complete remission without complete blood count recovery (CRi), including 5 patients achieving minimal residual disease (MRD) negative. After 2 courses of treatment, of 17 patients available for efficacy evaluation, 7 patients achieved MRD negative. Among 20 relapsed/refractory AML patients, 9 cases achieved CR/CRi after 1 course of treatment, of which 1 patient had MRD negative. Among 21 patients initially treated and re-treated, 13 cases achieved CR/CRi and 1 case achieved partial remission after 1 course of treatment, of which 4 cases had MRD negative.Conclusions:VEN-based treatment regimens for AML have a high remission rate and tolerable adverse effects.
